Clinical Trial Update: Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is recruiting to evaluate low-dose sirolimus for post-acute sequelae of SARS-CoV-2 infection (Long COVID). The study is sponsored by Ic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Long COVID-19 | Phase 3 | Status: RECRUITING